
Amidst projected surges in the physician-dispensed skin care market, Carmell Cosmetics has acquired Elevai Labs, a manufacturer of physician-dispensed, exosome-based products to deepen Carmell’s advancement: secretomes. According to Straits Research, the physician dispensed market size was valued at $10.7 billion in 2023 and is estimated to reach $23.83 billion by 2032, growing at a CAGR of 8.3%.
Log in to view the full article
Amidst projected surges in the physician-dispensed skin care market, Carmell Cosmetics has acquired Elevai Labs, a manufacturer of physician-dispensed, exosome-based products to deepen Carmell’s advancement: secretomes. According to Straits Research, the physician dispensed market size was valued at $10.7 billion in 2023 and is estimated to reach $23.83 billion by 2032, growing at a CAGR of 8.3%.
Patients have shown increased interest in clinically proven skin care, particularly blending regenerative medicine that addresses signs of aging and rejuvenates without invasiveness. Carmell’s acquisition of Elevai combines Carmell’s “built by biology” philosophy with Elevai’s exosomes to replenish and stimulate the body’s natural regenerative processes, says Carmell Chairman Rajiv Shukla.
“Carmell now has the two most exciting and novel aesthetic technologies in the half-a-trillion-dollar cosmetics market under one platform,” Shukla says.
There is a synergy between the two brands, Shukla says – both representing two advancements in the bio-aesthetic industry – exosomes and secretomes. He says post-procedure care has driven the market for these innovations, as physicians increasingly recommend combination therapies that integrate skin care with dermatological treatments.
Unlocking One Another's Potential
In the wake of Carmell’s acquisition, Elevai recently expanded into the hair care market with its S-Series Root Renewal System, which combines exosome and mitochondrial technology. Carmell is currently in the process of launching hair care products in the market.
Together, Shukla says, Carmell and Elevai can better serve the MedSpa community.
Shukla says Elevai’s exosomes are derived from mesenchymal stem cells, making their efforts particularly compatible with Carmell’s compared to alternative exosome developers that derive exosomes from adipose tissue, platelets or botanical sources, he adds.
Similar to Carmell Secretome, Elevai exosomes work with the body’s natural regenerative processes and replenish rather than replace natural biology, making them a powerful acquisition, Shukla says.
“This acquisition deepens Carmell’s position as a market leading aesthetic technology company that provides skin care solutions that enhance in-office treatments,” Shukla says. “Patients will have a choice of products as well as formulation types–Carmell’s micellar micro-emulsion creme and Elevai’s exosome serum.”
Giving the Physicians What They Want: Mission Acquired
Patients are becoming more educated about skin care ingredients and their benefits, Shukla says, leading to an increased demand for products that are clinically proven to work while being less invasive and delivering results at home. He adds that patients have also taken interest in medical-grade products that enhance the benefits of in-office treatments and surgeries.
“The synergy between our products and professional treatments further drives demand for products dispensed by medical professionals,” Shukla says. “We anticipate more healthcare providers will integrate skin care into their practices, further propelling the growth of this sector.”
Carmell’s Secretome is a blend of up to 1,000 proteins, peptides and bio-lipids extracted from platelet rich plasma (PRP), Shukla says, including bisabolol, panthenol, allantoin, vitamin K and zinc oxide. Congruent with Carmell’s position as an aesthetic technology company that provides skin care to enhance in-office treatments, Elevai produces skin care meant to soothe and help rebuild the skin barrier for rejuvenation and recovery, he adds.
Shukla says Elevai and Carmell’s products will continue to be available in medical offices with broader distribution globally and domestically under the new acquisition.
“This acquisition further cements our position as the home of the best bio-aesthetic skin care science,” Shukla says. “With the acquisition of Elevai's commercial and product development team to complement the Carmell team, we are strongly positioned for the future.”
Editor's note: This story will be updated at a later date with commentary from Elevai.